US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The FDA has approved Ozempic for type 2 diabetes, but it’s also known for its use off-label for weight loss. The agency has authorized Novo Nordisk’s Wegovy—which shares the same active ...
Novo Nordisk has been one of the chief ... the company hopes will build on the success of flagship weight-loss treatments Wegovy and Ozempic. Like those injections, the new drug targets gut ...
The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% ... for Development at Novo Nordisk. "The results seen ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback